News|Articles|November 18, 2024
Elevating and De-Risking Your Drug Portfolio Strategy With AI
Author(s)Intelligencia AI
Artificial intelligence (AI) can improve risk assessment and decision-making in drug development by applying objective, data-driven criteria consistently. Companies should focus on the quality of data, selecting the right AI use cases, and leveraging external partners to maximize the potential of AI.
Related Content
Trending on PharmExec
1
Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio
2
Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata
3
Deepening Ties: Why China is Becoming Big Pharma's Most Essential R&D Partner
4
Pharmaceutical Executive Daily: Roche and Nurix Therapeutics Announce Global Collaboration
5